

# SCHERING CORPORATION

2000 GALLOPING HILL ROAD



KENILWORTH, N.J. 07033

TELEPHONE (908) 298-4000

February 4, 2005

Division of Dockets Management (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**RE: DOCKET NO.: 2003P-0029  
USE OF OZONE-DEPLETING SUBSTANCE; REMOVAL OF ESSENTIAL  
USE DESIGNATIONS**

Dear Sir or Madam,

Please refer to Schering-Plough's previous submission to the docket dated January 28, 2005 and received by FDA January 31, 2005 (provided in **Attachment 1** of this submission for reference). This submission inadvertently contained a confidentiality statement. Schering-Plough intended this submission to be submitted to the public docket and to be available in the public domain.

We authorize and consent the FDA to release the above referenced letter in the docket for public disclosure. This consent for disclosure specifically includes the information above that was labeled 'confidential'.

Sincerely,

Ronald J. Garutti, MD  
Group Vice President  
Global Regulatory Affairs

RG/am

cc: Robert Meyer, M.D.  
Director, Office of Drug Evaluation II  
OND/CDER/FDA

Badrul Chowdhury, M.D.  
Director, Division of Allergy and Pulmonary Drug Products  
ODEII/OND/CDER/FDA

Wayne H. Mitchell, Esq.  
Center for Drug Evaluation Research (HFD-7)  
FDA

**2003P-0029**

**CR 2**